Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

ECTRIMS 2024 HIGHLIGHTS – THURSDAY, SEPTEMBER 19, 2024

…tant changes to the diagnosis of MS were introduced in the revised McDonald 2024 criteria (Montalban et al. ECTRIMS 2024;SS1). MS is no longer strictly a clinical diagnosis: paraclinical evidence of an abnormal brain/spinal MRI is required. In addition to brain/spinal cord lesions, dissemination in space (DIS) criteria now include the optic nerve as a fifth topography. Optic nerve pathology may be demonstrated with MRI, visual evoked potentials (V…

ECTRIMS 2024 slide resource

…now by completing the online form. Industry members can also use this form to request to sponsor a NeuroSens post-ECTRIMS event (in-person or virtual). For more information, contact us at info@neuro-sens.com. In the meantime, check out our Daily Highlights report….

ECTRIMS 2024 HIGHLIGHTS – WEDNESDAY, SEPTEMBER 18, 2024

…f relapse during pregnancy or in the one year postpartum. Relapse was most common in the first trimester and commonly involved isolated sensory deficits. There was a higher risk of relapse in women with spinal lesions at the time of diagnosis and conception. Disability progression in the one year postpartum was more likely in women who relapsed during pregnancy or the first postpartum year compared to those who did not relapse (25.8% vs. 5.5%). Re…

ECTRIMS 2024 survey

…ropean Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 annual meeting, to be held September 18-20, 2024. You can help us fine-tune our reporting by completing the survey below. Thank you! Question 1: Which of the following hot topics is most interesting/relevant to you? (pick 2) Prodromal MS and RIS Menopause and sexual dysfunction Neuroprotective therapies Symptom management: fatigue and sleep Antibody-mediated demyelina…

Meta-analysis of CBD meta-analyses reports efficacy in younger patients with seizure disorders

…(DS) and tuberous sclerosis complex (TSC) (Borowicz-Reutt et al. Molecules 2024;29:1981). CBD is a phytocannabinoid with known anticonvulsant effects although its mechanism of action is not well-established. CBD has low affinity for cannabinoid receptors so its effects do not appear to be via agonism of the CB1 or CB2 receptors. Rather, the antiseizure properties of CBD may be through modulation of ion channels, inhibition of adenosine reuptake,…